Although more than half of patients with EGFR-mutant NSCLC initially show response to gefitinib, most of them have to face the fate of acquired drug resistance which is mainly due to the emergence of the T790 M mutation,15 resulting in a median PFS of merely 12–14 months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.